The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Open accessAbstract
Purpose: Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy and tolerability of pralatrexate, a novel antifolate with promising activity. Patients and Methods: Patients with independently confirmed PTCL who progressed following ≥ 1 line of prior therapy received pralatrexate intravenously at 30 mg/m 2 /wk for 6 weeks in 7-week cycles. Primary assessment of response was made by independent central review using the International Workshop Criteria. The primary end point was overall response rate. Secondary end points included duration of response, progression-free survival (PFS), and overall survival (OS). Results: Of 115 patients enrolled, 111 were treated with pralatrexate. The median number of prior systemic therapies was three (range, 1 to 12). The response rate in 109 evaluable patients was 29% (32 of 109), including 12 complete responses (11%) and 20 partial responses (18%), with a median DoR of 10.1 months. Median PFS and OS were 3.5 and 14.5 months, respectively. The most common grade 3/4 adverse events were thrombocytopenia (32%), mucositis (22%), neutropenia (22%), and anemia (18%). Conclusion: To our knowledge, PROPEL (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) is the largest prospective study conducted in patients with relapsed or refractory PTCL. Pralatrexate induced durable responses in relapsed or refractory PTCL irrespective of age, histologic subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant. These data formed the basis for the US Food and Drug Administration approval of pralatrexate, the first drug approved for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationThe Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,461
International T-Cell Lymphoma Project (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4558 · Cited by 2,108
Armitage, J. O., & Weisenburger, D. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2780 · Cited by 1,251
Rüdiger, T., Weisenburger, D. D., Anderson, J. R., Armitage, J. O., Diebold, J., MacLennan, K. A., Nathwani, B. N., Ullrich, F., & Müller-Hermelink, H. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf033 · Cited by 419
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., & Vardiman, J. (2000) · Annals of Oncology · doi:10.1093/annonc/11.suppl_1.s3 · Cited by 329
O'Connor, O. A., Horwitz, S., Hamlin, P., Portlock, C., Moskowitz, C. H., Sarasohn, D., Neylon, E., Mastrella, J., Hamelers, R., MacGregor-Cortelli, B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8470 · Cited by 187
Self-citationWang, E. S., O’Connor, O. A., She, Y., Zelenetz, A. D., Sirotnak, F. M., & Moore, M. A. S. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000077124 · Cited by 116
Self-citationMarchi, E., Paoluzzi, L., Scotto, L., Seshan, V., Zain, J. M., Zinzani, P. L., & O’Connor, O. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0671 · Cited by 79
Self-citationToner, L. E., Vrḫovac, R., Smith, E. A., Gardner, J. R., Heaney, M. L., Gönen, M., Teruya‐Feldstein, J., Sirotnak, F. M., & O’Connor, O. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0331 · Cited by 71
Self-citation
Cited by
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Self-citationCoiffier, B., Pro, B., Prince, H. M., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Borchmann, P., Morschhauser, F., Wilhelm, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4223 · Cited by 680
Self-citationUp-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Österborg, A., Merup, M., Brown, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.2719 · Cited by 594
O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Self-citation
Metadata
- Authors
- O'Connor, O. A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Jo Lechowicz, M., Savage, K. J., Shustov, A. R., Gisselbrecht, C., Jacobsen, E., Zinzani, P. L., Furman, R., Goy, A., Haioun, C., Crump, M., Zain, J. M., Hsi, E., Boyd, A., & Horwitz, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-20
- Volume
- 29
- Issue
- 9
- Pages
- 1182-1189
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2146112074
- Cited by
- 647
- References
- 13
- FWCI
- 33.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.